HALBERD CORP - HALB STOCK NEWS

Halberd Corporation (OTC PINK:HALB) has successfully removed Interleukin-6 (IL-6) from human blood serum in recent laboratory tests. IL-6 is linked to inflammation and diseases like rheumatoid arthritis and certain cancers. Unlike previous methods using laser irradiation on cerebrospinal fluid, this new approach employs a specially engineered antibody bonded to a microbead filter. The CEO highlighted the platform's potential for universal application in treating various diseases. The company has also secured exclusive rights to three patents, enhancing its value for shareholders.

Halberd Corporation (OTC PINK:HALB) announced a strategic alliance with AI Longevity, Inc. and Stem of Hope to create a subsidiary named Extendalife focused on longevity and treatments for Alzheimer's Disease and Cancer. The alliance aims to leverage patented technologies for disease treatment and longevity enhancement.

The team plans to start animal testing by year-end, with expectations for initial feasibility results in improving longevity. Halberd intends to spin off Extendalife as a publicly traded entity, granting shares to current shareholders, enhancing potential shareholder value.

Halberd Corporation (OTC PINK:HALB) has successfully demonstrated the ability to control PD-1 levels in human blood serum during lab tests. This process, which can effectively eliminate PD-1, could empower the body's immune system to target cancer tumors more effectively. The company’s patented technique offers a swift restoration of PD-1 levels, potentially revolutionizing cancer immunotherapy. Both Dr. Mitchell S. Felder and CEO William A. Hartman expressed optimism regarding the implications of these results for safer and more effective cancer treatments.

Halberd Corporation (OTC PINK:HALB) received a significant endorsement from Carl Eller, President of the NFL Retired Players Association, for its innovative treatments targeting Traumatic Brain Injury (TBI) and related neurodegenerative diseases. This endorsement follows Halberd's research showing effective in-vitro elimination of inflammatory cytokines linked to head trauma. Halberd's leadership, including CEO William A. Hartman, expressed optimism for further collaboration with sports organizations. The company holds exclusive rights to multiple patents, enhancing its market value.

Halberd Corporation (OTC PINK:HALB) has established a wholly-owned subsidiary named Halberd Cancer Therapeutics, LTD. This move aims to leverage Halberd's patented extracorporeal technology for developing cancer treatments. Initially staffed by Halberd employees, the subsidiary may eventually evolve into a standalone company, potentially benefiting stockholders through dividends. The company is also progressing on specific cancer antibodies for near-term experimentation, indicating a focus on innovative cancer therapies.

Halberd Corporation (OTC PINK:HALB) announced a breakthrough in Covid-19 treatment, with a proprietary monoclonal antibody that enhances the effectiveness of a leading commercial Covid-19 antibody from 65% to 94%. This antibody is effective against all current SARS-CoV-2 mutations including Omicron. Their research emphasizes the potential for widespread treatment against evolving variants. CEO William A. Hartman mentions ongoing discussions for potential patents stemming from these promising results, which could attract further industry interest.

Halberd Corporation (OTC PINK:HALB) reported significant technical and organizational milestones for Q2 2022, ending June 30. The company added animal testing expertise to enhance its patented process for removing disease antigens. A scientific article is in review for patent protection, while outreach for endorsements from the NFL and NCAA is ongoing. Halberd is exploring FDA authorization for its technology and submitted audited financials to the SEC for OTCQB uplisting. Future plans include animal testing and potential spin-offs of specialized subsidiaries, broadening treatment options for various diseases.

Halberd Corporation (OTC PINK:HALB) has announced the formation of a specialized subgroup to focus on cancer treatment leveraging its patented extracorporeal treatment approach. This new division will operate alongside ongoing efforts in neurodegenerative diseases. The company aims to develop three significant cancer antibodies (PD-1, BTLA, CTLA-4) and anticipates potential spin-off opportunities for shareholders. The CEO highlighted that this initiative may enhance both treatment efficacy and shareholder value without compromising existing projects.

Halberd Corporation (OTC PINK:HALB) has signed a non-disclosure agreement with Mississippi State University to conduct animal testing aimed at obtaining FDA certification for its disease eradication technology. Following proof-of-concept success in eliminating antigens linked to neurodegenerative diseases, this step is crucial for the development of effective treatments. The company aims to optimize research resources while preparing for clinical trials. Leadership expresses eagerness to engage with testing experts to refine processes for potential FDA approval.